Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1186/s13023-015-0338-2 http://scihub22266oqcxt.onion/10.1186/s13023-015-0338-2 C4587871!4587871!26416388     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 247.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Orphanet+J+Rare+Dis 2015 ; 10 (ä): ä Nephropedia Template TP {{tp|p=26416388|t=2015. Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years? treatment |pdf=|usr=}}{{26416388}} gab.com Text Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years treatment JO: Orphanet J Rare Dis http://www.kidney.de/pget.php?&tw=1&pmid=26416388 #FOAvip Background: To explore long-term effects of agalsidase alfa on Fabry disease cardiomyopathy in adults. Methods: Retrospective analysis of prospectively collected data at a single center in Mainz, Germany, revealed that 45 adult patients (21 men, 24 women) had received agalsidase alfa for approximately 10 years. Data were extracted for cardiac and heart failure status, echocardiographic evaluations of cardiac structure and function, and renal function at treatment start and during agalsidase alfa treatment. Results: After 10 years of agalsidase alfa treatment, heart failure classification had improved by at least 1 class in 22/42 patients, and angina scores were stable or improved in 41/42 patients. During treatment, no patients without left ventricular hypertrophy (LVH) at treatment initiation developed LVH, and no patients with LVH at treatment initiation showed a decline in left ventricular mass. Conclusions: Approximately 10 years of agalsidase alfa treatment appeared to have beneficial effects for controlling progression and improving some symptoms of Fabry-associated cardiomyopathy. Twit Text FOAVip Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years treatment ????Orphanet J Rare Dis http://www.kidney.de/pget.php?&tw=1&pmid=26416388 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26416388 #FOAvip English Wikipedia <ref>{{Cite pmid|26416388}}</ref> Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years? treatment #MMPMID26416388 Kampmann C; Perrin A; Beck M Orphanet J Rare Dis 2015[]; 10 (ä): ä PMID26416388show ga Background: To explore long-term effects of agalsidase alfa on Fabry disease cardiomyopathy in adults. Methods: Retrospective analysis of prospectively collected data at a single center in Mainz, Germany, revealed that 45 adult patients (21 men, 24 women) had received agalsidase alfa for approximately 10 years. Data were extracted for cardiac and heart failure status, echocardiographic evaluations of cardiac structure and function, and renal function at treatment start and during agalsidase alfa treatment. Results: After 10 years of agalsidase alfa treatment, heart failure classification had improved by at least 1 class in 22/42 patients, and angina scores were stable or improved in 41/42 patients. During treatment, no patients without left ventricular hypertrophy (LVH) at treatment initiation developed LVH, and no patients with LVH at treatment initiation showed a decline in left ventricular mass. Conclusions: Approximately 10 years of agalsidase alfa treatment appeared to have beneficial effects for controlling progression and improving some symptoms of Fabry-associated cardiomyopathy. äEffectiveness of agalsidase alfa enzyme replacement in Fabry disease: (epmc).pdf DeepDyve Pubget Overpricing